Alterity Therapeutics (ATHE) Competitors $3.44 -0.06 (-1.71%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$3.44 0.00 (0.00%) As of 03/28/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. MCRB, FTLF, MGNX, VIRI, VXRT, EDIT, ELUT, RENB, TLSA, and ADVMShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Seres Therapeutics (MCRB), FitLife Brands (FTLF), MacroGenics (MGNX), Virios Therapeutics (VIRI), Vaxart (VXRT), Editas Medicine (EDIT), Elutia (ELUT), Renovaro (RENB), Tiziana Life Sciences (TLSA), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Seres Therapeutics FitLife Brands MacroGenics Virios Therapeutics Vaxart Editas Medicine Elutia Renovaro Tiziana Life Sciences Adverum Biotechnologies Seres Therapeutics (NASDAQ:MCRB) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has more volatility and risk, MCRB or ATHE? Seres Therapeutics has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Is MCRB or ATHE more profitable? Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A N/A -55.08% Alterity Therapeutics N/A N/A N/A Does the media prefer MCRB or ATHE? In the previous week, Seres Therapeutics had 2 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Seres Therapeutics and 4 mentions for Alterity Therapeutics. Seres Therapeutics' average media sentiment score of 1.07 beat Alterity Therapeutics' score of 0.42 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, MCRB or ATHE? Alterity Therapeutics has lower revenue, but higher earnings than Seres Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres Therapeutics$126.33M1.00-$113.72M-$0.23-3.13Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the MarketBeat Community believe in MCRB or ATHE? Seres Therapeutics received 526 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 71.47% of users gave Seres Therapeutics an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote. CompanyUnderperformOutperformSeres TherapeuticsOutperform Votes53171.47% Underperform Votes21228.53% Alterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% Do institutionals & insiders have more ownership in MCRB or ATHE? 59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate MCRB or ATHE? Seres Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 454.79%. Alterity Therapeutics has a consensus target price of $12.00, indicating a potential upside of 248.84%. Given Seres Therapeutics' higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummarySeres Therapeutics beats Alterity Therapeutics on 9 of the 13 factors compared between the two stocks. Remove Ads Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.50M$6.90B$5.63B$7.84BDividend YieldN/A2.76%5.33%4.01%P/E RatioN/A7.2623.5518.73Price / SalesN/A218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book3.316.386.894.23Net Income-$12.54M$142.34M$3.20B$247.47M7 Day Performance-8.75%-5.15%-3.06%-2.29%1 Month Performance-13.22%-7.55%1.51%-5.81%1 Year Performance66.18%-11.06%9.37%-0.96% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.4039 of 5 stars$3.44-1.7%$12.00+248.8%+66.2%$30.50MN/A0.0010Short Interest ↓News CoverageMCRBSeres Therapeutics3.3505 of 5 stars$0.71+0.3%$4.00+460.9%-6.9%$124.34M$126.33M-3.10330Analyst RevisionPositive NewsFTLFFitLife Brands4.4732 of 5 stars$13.23-1.9%$20.50+55.0%+5.9%$124.15M$62.76M15.6620Earnings ReportShort Interest ↓Analyst RevisionNews CoverageMGNXMacroGenics3.8766 of 5 stars$1.96-1.8%$7.63+289.0%-91.4%$123.02M$148.34M-1.24430Analyst ForecastAnalyst RevisionVIRIVirios Therapeutics0.3928 of 5 stars$6.33-7.3%$3.00-52.6%+1,077.2%$121.90MN/A-23.445News CoverageGap UpVXRTVaxart2.202 of 5 stars$0.51-0.7%$4.00+680.3%-67.6%$116.61M$28.70M-1.25120Analyst ForecastAnalyst RevisionNews CoverageEDITEditas Medicine3.9881 of 5 stars$1.39+6.1%$6.83+391.6%-83.2%$115.34M$32.31M-0.54230Analyst RevisionELUTElutia3.9292 of 5 stars$2.81-3.8%$9.00+220.3%-16.2%$114.47M$24.38M-1.08180Short Interest ↓News CoverageRENBRenovaro1.069 of 5 stars$0.72+2.6%N/A-78.1%$114.04MN/A-0.7720Positive NewsGap DownTLSATiziana Life Sciences0.6132 of 5 stars$1.08-2.7%N/A+146.7%$113.83MN/A0.008Short Interest ↑ADVMAdverum Biotechnologies4.4034 of 5 stars$5.40+5.9%$27.83+415.4%-67.4%$112.33M$1M-0.90190Upcoming EarningsInsider TradeNews CoveragePositive News Remove Ads Related Companies and Tools Related Companies MCRB Competitors FTLF Competitors MGNX Competitors VIRI Competitors VXRT Competitors EDIT Competitors ELUT Competitors RENB Competitors TLSA Competitors ADVM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump's 100-Day Plan Triggers Global RetaliationIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATHE Stock Free ATHE Stock Alerts